Latest News & Features
Big Pharma
Teva has filed a complaint against nine pharmaceutical companies including Dr Reddy's Laboratories, Sandoz and Mylan for alleged patent infringement over Copaxone, a treatment for patients with multiple sclerosis. 23 December 2016
Americas
Pfizer has agreed a collaboration and licensing agreement with Sweden-based pharmaceutical company BioInvent International on cancer immunotherapy research. 22 December 2016
Americas
Millennium Pharmaceuticals, now known as Takeda Oncology, has filed a complaint against US-based MSN Laboratories for patent infringement of Velcade, a treatment for cancer. 22 December 2016
Big Pharma
A combination of patents, SPCs and regulatory exclusivities should be considered carefully in order to maximise the exclusivity available for cell therapies, as Glyn Truscott of Elkington + Fife explains. 22 December 2016
Americas
Ethicon Endo Surgery, a subsidiary of Johnson & Johnson, has filed a complaint for declaratory judgment of non-infringement against Covidien, which is owned by Medtronic. 21 December 2016
Asia-Pacific
Phylogica, an Australian drug discovery company, has extended its research collaboration and licensing agreement with Genentech to discover novel antibiotics. 21 December 2016
Americas
Sloan Kettering Institute for Cancer Research, based in New York, and Juno Therapeutics have filed a complaint for declaratory judgment of patent infringement against Kite Pharma. 20 December 2016
article
Marc Doring of Allen & Overy discusses his reaction to the UK government’s announcement that it will ratify the UPC, at the Life Sciences Patents Network Europe 2016, held in London by LSIPR. 20 December 2016
article
Nicola Dagg of Allen & Overy discusses what is on the horizon for 2017 at both the Court of Appeal and the UK Supreme Court, at the Life Sciences Patents Network Europe 2016, hosted in London by LSIPR. 20 December 2016
article
Life Sciences Patents Network Europe 2016: Video interview with Sven Bostyn, University of Liverpool
“The regulatory system has to be amended,” says Sven Bostyn of the University of Liverpool, when talking about second medical use patents at the Life Sciences Patents Network Europe 2016, hosted by LSIPR in London. 20 December 2016